High expression of PCBP2 is associated with progression and poor prognosis in patients with glioblastoma

BackgroundPoly(C)‐binding protein 2 (PCBP2) has been found to have ambiguous functions in a variety of cancers. However, the specific biological function of PCBP2 and its mechanism in glioblastoma remain unclear. We investigated the expression of PCBP2 in 143 glioblastoma specimens to explore the linkage between PCBP2 expression and clinicopathological parameters as well as clinical significance. Furthermore, the underlying mechanisms of PCBP2 on glioblastoma progression were discussed in vitro.MethodsThe transcriptional and translational levels of PCBP2 in 143 glioblastoma patients were detected by quantitative Real-time PCR (qRT-PCR) and western blot. The association of prognostic outcomes and PCBP2 expression was evaluated using Kaplan-Meier analysis.ResultsPCBP2 expression was markedly increased in higher stages of glioblastoma compared with those in lower stages (P < 0.001). High expression of PCBP2 was associated with higher clinical stage and histological grade (P < 0.001). Further research suggested that PCBP2 upregulation was connected with poorer prognosis in patients with glioblastoma (P < 0.001). Moreover, PCBP2 knockdown could significantly decreased the colony formation and invasion capability of glioblastoma cells (P < 0.01). Conversely, PCBP2 overexpression could increase the colony formation and invasion capability (P < 0.01).ConclusionThese findings indicated that PCBP2 might be a novel prognostic biomarker and a potential therapeutic target of glioblastoma.